Hosted on MSN1mon
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary ...
Business Wire1mon
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq ... today announced that it has received the final full data set from its multiple ascending dose clinical trial for AL001 treatment of ...